# Twist Bioscience Corp (TWST) — capital_raise/public_offering [pending]
Source: SEC API (secapi.ai) · situation sit_0be6f9c7c0940ca546d8 · retrieved 2026-08-12T07:20:31.675Z

## Overview
Twist Bioscience Corporation is a biological products company that develops synthetic biology solutions for research and industrial applications.

Twist Bioscience Corporation entered into an underwriting agreement on August 4, 2026 with Goldman Sachs & Co. LLC, William Blair & Company, L.L.C., Leerink Partners LLC, and Guggenheim Securities, LLC to issue and sell 3,125,000 shares of common stock at a public offering price of $96.00 per share. The underwriters exercised their option on August 5, 2026 to purchase an additional 468,750 shares at the same price. The net proceeds to the Company from the offering, including the exercise of the option, are expected to be approximately $327.1 million after deducting underwriting discounts, commissions, and estimated offering expenses. The offering is expected to close on or about August 6, 2026, subject to customary closing conditions.

## Terms
- Counterparty: Goldman Sachs & Co. LLC, William Blair & Company, L.L.C., Leerink Partners LLC, and Guggenheim Securities, LLC · Deal value: $327.1M · Consideration: cash · Price/share: $96

## Key dates
- Announced 2026-08-05 · Expected close 2026-08-06

## Timeline
- 2026-08-05 · 8-K (0001104659-26-091280): 8-K - Twist Bioscience Corp — *Twist Bioscience Corporation is a biological products company that develops synthetic biology solutions for research and industrial applications.* Twist Bioscience Corporation entered into an underwriting agreement on August 4, 2026 with Goldman Sachs & Co. LLC, William Blair & Company, L.L.C., Leerink Partners LLC, and Guggenheim Securities, LLC to issue and sell 3,125,000 shares of common stock at a public offering price of $96.00 per share. The underwriters exercised their option on August 5, 2026 to purchase an additional 468,750 shares at the same price. The net proceeds to the Company from the offering, including the exercise of the option, are expected to be approximately $327.1 million after deducting underwriting discounts, commissions, and estimated offering expenses. The offering is expected to close on or about August 6, 2026, subject to customary closing conditions.
  https://www.sec.gov/Archives/edgar/data/1581280/0001104659-26-091280.txt

## Citations
- 0001104659-26-091280 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926091280